HEALTHJun 2 · 15:04 UTCSTAT NEWSElaine Chen

STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting

A radiopharmaceutical shows promise in the post-Pluvicto setting. Vera Therapeutics and the FDA agreed to accelerate analysis of a Phase 3 study for atacicept in treating IgA nephropathy, while Abivax reported positive data for an ulcerative colitis treatment despite cancer concerns.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Vera TherapeuticsorganizationFDAorganizationAbivaxorganizationatacicepttopicPluvictotopicIgA nephropathytopiculcerative colitistopiccancertopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 5 · 05:05 UTC
STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
HEALTHJun 1 · 21:31 UTC
STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
HEALTHJun 1 · 00:00 UTC
Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments
HEALTHJun 1 · 13:30 UTC
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
HEALTHMay 3 · 17:23 UTC
FDA expanding access to pancreatic cancer drug to some patients
HEALTHMay 15 · 03:32 UTC
WATCH: How a new drug could lengthen lives of pancreatic cancer patients